Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.
Anti-angiogenic therapies, including bevacizumab, are being used with increasing frequency in the management of malignant glioma. Common clinically significant toxicities include hypertension and proteinuria, poor wound healing, and the potential for thromboembolic events. Literature related to the use of bevacizumab in malignant glioma, reported toxicities in this patient population, and management of these toxicities was reviewed. Recommendations for assessment and management are provided. Anti-angiogenic therapies will continue to have a role in the treatment of malignant glioma. Further studies of the prevention, assessment, and management of these toxicities are warranted.
Department of Integrative Nursing Care, UTHSC-SON, USA. terri.s.armstrong@uth.tmc.edu
Terri S
TS
Armstrong
Patrick Y
PY
Wen
Mark R
MR
Gilbert
David
D
Schiff
D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D001932:Brain Neoplasms / Q000188:drug therapy*; D019468:Disease Management; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D009389:Neovascularization, Pathologic / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors